Latest News

Oil Traders Selling Pricey Russian Crude Chafe Indian Refiners



RedHill pill shows promise vs Omicron; mRNA vaccines appear effective in those with well-controlled HIV

An experimental drug being developed by RedHill Biopharma Ltd that improved outcomes in a randomized trial involving severely ill COVID-19 patients infected with earlier versions of the coronavirus is showing promise against the Omicron variant in test tube experiments, researchers said. When opaganib was added to treatment with Gilead Sciences’ remdesivir and corticosteroids in hospitalized patients infected before Omicron was predominant, it improved the average time until patients no longer had detectable virus in their blood by four days, sped up recovery by 34%, and reduced mortality by 70%, compared to a placebo, according to data released previously by the company but not yet formally published. On Monday, the company announced that in lab experiments, opaganib kept Omicron virus particles from reproducing themselves.

Procter & Gamble hikes dividend by 5%

Previous article

Nvidia Stock Loses a Wall Street Supporter

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News